Patents Examined by Golam M. Shameem
  • Alkoxylated secondary alcohol sulfates
    Patent number: 11339123
    Abstract: The invention relates to the compounds of formula (I), in which R1 and R2 represent a linear, branched or cyclic, saturated or unsaturated hydrocarbon group, comprising 1 to 6 carbon atoms, wherein the sum of the carbon atoms of the groups R1 and R2 is from 2 to 7; A represents a chain of one or a plurality of units of ethylene oxide, propylene oxide, butylene oxide and mixtures thereof; and n is an integer between 1 and 100 inclusive. The invention also relates to mineral or organic salts thereof; the use of the compounds of formula (I) and/or of one of the salts thereof as a surfactant, a wetting agent, a detergent, an emulsifying agent, a dispersant, a corrosion inhibitor, and the like; and to compositions comprising at least one compound of formula (I) and/or of one of the salts thereof.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: May 24, 2022
    Assignee: Arkema France
    Inventors: Jean-Philippe Gillet, Juan Antonio Gonzalez Leon, Carl Bouret
  • Polyketide compound and derivatives thereof for use in the prevention and treatment of a neurological disorder
    Patent number: 11339111
    Abstract: The present invention relates to a compound, in particular a polyketide compound and derivatives thereof, for use in the prevention and/or treatment of a neurological disorder in an individual. The compound of the invention can promote lactate secretion. A composition comprising the compound of the invention, and a food or food extract enriched with said compound or composition are also provided.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: May 24, 2022
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Denis Marcel Barron, Olivier Ciclet, Alexandre Grand-Guillaume-Perrenoud, Martine Naranjo Pinta, Yann Ratinaud, Jonathan Thevenet, Andreas Wiederkehr
  • Identification of stabilizers of multimeric proteins
    Patent number: 11337935
    Abstract: Disclosed herein are compounds and compositions thereof which find use in increasing stability of TTR tetramers reducing its tendency to misfold and form aggregates. Also provided herein are methods for using these compounds and compositions for increasing stability of TTR and thereby decreasing aggregate formation by TTR. Also disclosed herein are methods to screen for candidate compounds that increase stability of TTR. Also disclosed herein are heterobifunctional compounds that include a TTR binding compound connected to a targeting moiety via a linker, for use in disrupting PPIs of a target protein.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: May 24, 2022
    Inventors: Isabella A. Graef, Mamoun M. Alhamadsheh
  • Imidazole and triazole containing bicyclic compounds as JAK inhibitors
    Patent number: 11339160
    Abstract: The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat gastrointestinal and other inflammatory diseases.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: May 24, 2022
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Robert Murray McKinnell, Erik Fenster, Tom M. Lam, Anthony Francesco Palermo
  • Method for the hydrolysis of quinolonecarboxylic esters
    Patent number: 11332444
    Abstract: Quinolonecarboxylic esters of the general formula (II) are hydrolyzed to quinolonecarboxylic acids of the general formula (I): The method comprises the step A): A) reacting compounds of the formula (II) with a mixture comprising acetic acid, sulfuric acid and water In step A), ?30 to ?40 mol of acetic acid, ?0.3 to ?1 mol of sulfuric acid and ?0.9 to ?2.5 mol of water are used per mole of compounds of the formula (II). The method is particularly suitable for the synthesis of the intermediate (I) in the synthesis of pradofloxacin.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: May 17, 2022
    Assignee: Bayer Animal Health GmbH
    Inventors: Peter Fey, Mathias Berwe, Joerg Wirths, Ralf Wischnat, Markus Longerich, Antje Dietzel
  • Process for the conversion of a solid lignocellulosic material
    Patent number: 11332454
    Abstract: A process for the conversion of solid lignocellulosic material containing hemicellulose, cellulose and lignin, includes (a) hydrolyzing, at a temperature equal to or less than 40° C. at least part of the hemicellulose and at least part of the cellulose of the solid lignocellulosic material with an aqueous hydrochloric acid solution, containing in the range from equal to or more than 40.0 wt. % to equal to or less than 51.0 wt. % hydrochloric acid, based on the combined weight amount of water and hydrochloric acid in the aqueous hydrochloric acid solution; yielding a hydrochloric acid-containing, aqueous hydrolysate solution; (b) separating the hydrochloric acid-containing, aqueous hydrolysate solution from the lignin; and (c) heating at least part of the hydrochloric acid-containing, aqueous hydrolysate solution to a temperature equal to or more than 60° C.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: May 17, 2022
    Assignee: Furanix Technologies B.V.
    Inventors: Robert-Jan van Putten, Benjamin McKay, Gerardus Johannes Maria Gruter, Jan Cornelis van der Waal
  • Prodrugs of prostate specific membrane antigen (PSMA) inhibitor
    Patent number: 11325931
    Abstract: Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: May 10, 2022
    Assignees: The Johns Hopkins University, Inst of Organic Chem. and Biochemistry AS CR V.V.I
    Inventors: Barbara Slusher, Rana Rais, Marcela Krecmerova, Tomas Tichy, Pavel Majer, Andrej Jancarik
  • Benzenesulfonamide compounds and their use as therapeutic agents
    Patent number: 11325902
    Abstract: This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: May 10, 2022
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Kristen Nicole Burford, Thilo Focken, Verner Alexander Lofstrand, Michael Scott Wilson, Alla Yurevna Zenova
  • Metabolism resistant fenfluramine analogs and methods of using the same
    Patent number: 11325882
    Abstract: Metabolism-resistant fenfluramine analogs are provided. The subject fenfluramine analogs find use in the treatment of a variety of diseases. For example, methods of treating epilepsy by administering a fenfluramine analog to a subject in need thereof are provided. Also provided are methods of suppressing appetite in a subject in need thereof. Pharmaceutical compositions for use in practicing the subject methods are also provided.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: May 10, 2022
    Assignee: ZOGENIX INTERNATIONAL LIMITED
    Inventors: Stephen J. Farr, Brooks M. Boyd
  • 2,3-dihydrobenzohurans as bromodomain inhibitors
    Patent number: 11319307
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: May 3, 2022
    Assignee: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Stephen John Atkinson, Emmanuel Hubert Demont, Lee Andrew Harrison, Simon Christopher Cranko Lucas, Alexander G. Preston, Jonathan Thomas Seal, Ian David Wall, Robert J. Watson, James Michael Woolven
  • Benzofuran, benzothiophene, and indole analogs that inhibit the formation of tau oligomers and their method of use
    Patent number: 11306075
    Abstract: Novel benzofurans, benzothiophenes and indoles useful as inhibitors of tau oligomer formation, useful for the treatment of neurodegenerative diseases and related conditions are disclosed. The invention also relates to the pharmaceutically acceptable salts of said compounds, processes for the preparation of said compounds, intermediates used in the preparation of said compounds, and pharmaceutical compositions containing said compounds. The invention further relates to methods of use of said compounds, salts of said compounds, and said compositions in treating neurodegenerative diseases and related conditions.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: April 19, 2022
    Assignee: Oligomerix, Inc.
    Inventors: Eliot J. Davidowitz, James G. Moe, Allen B. Reitz, Haiyan Bian, Charles Gluchowski, James Hendrix, Albert S. Yehaskel, Mark E. McDonnell, H. Marie Loughran
  • Chemical compounds
    Patent number: 11306108
    Abstract: The present invention describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the invention have activity as Janus kinase (JAK) inhibitors and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described herein are methods of treating inflammation, auto-immune diseases, cancer, and other conditions susceptible to inhibition of JAK by administering a compound herein described.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: April 19, 2022
    Assignee: Borah, Inc.
    Inventors: Yasheen Zhou, Chunliang Liu, Yong-Kang Zhang, Marissa Aubrey, Chun Yu Liu
  • Benzenesulfonamide compounds and their use as therapeutic agents
    Patent number: 11299490
    Abstract: This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.
    Type: Grant
    Filed: July 28, 2020
    Date of Patent: April 12, 2022
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Jean-Christophe Andrez, Kristen Nicole Burford, Sultan Chowdhury, Charles Jay Cohen, Christoph Martin Dehnhardt, Robert Joseph Devita, James Roy Empfield, Thilo Focken, Michael Edward Grimwood, Syed Abid Hasan, James Philip Johnson, Jr., Alla Yurevna Zenova
  • Treatment of circadian rhythm disorders
    Patent number: 11285129
    Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
    Type: Grant
    Filed: July 6, 2021
    Date of Patent: March 29, 2022
    Assignee: VANDA PHARMACEUTICALS INC.
    Inventors: Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
  • Benzofuran derivatives and their use as bromodomain inhibitors
    Patent number: 11273146
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: March 15, 2022
    Assignee: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Stephen John Atkinson, Emmanuel Hubert Demont, Lee Andrew Harrison, Simon Christopher Cranko Lucas, Alexander G. Preston, Jonathan Thomas Seal, Ian David Wall, Robert J. Watson, James Michael Woolven
  • Arginase inhibitors and methods of use
    Patent number: 11274111
    Abstract: Described herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof. The compounds of Formula (I) act as arginase inhibitors and can be useful in preventing, treating or acting as a remedial agent for arginase-related diseases.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: March 15, 2022
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Abdelghani Abe Achab, Jared N. Cumming, Christian Fischer, Symon Gathiaka, Charles A. Lesburg, Derun Li, Min Lu, Matthew J. Mitcheltree, Anandan Palani, Rachel L. Palte, David L. Sloman, Hongjun Zhang
  • NK-1 antagonist compositions and methods for use in treating depression
    Patent number: 11266633
    Abstract: The present invention describes the combination of a NK1-antagonist with pramipexole or a pharmaceutically acceptable salt or solvate thereof, useful for treating depressive disorders, including major depressive disorder.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: March 8, 2022
    Assignee: CHASE THERAPEUTICS CORPORATION
    Inventors: Thomas N. Chase, Kathleen E. Clarence-Smith
  • Benzothia(di)azepine compounds and their use as bile acid modulators
    Patent number: 11267794
    Abstract: The invention relates to certain 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives as defined herein. These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
    Type: Grant
    Filed: January 8, 2021
    Date of Patent: March 8, 2022
    Assignee: Albireo AB
    Inventors: Per-Göran Gillberg, Ingemar Starke, Santosh S. Kulkarni
  • Oral formulations of belinostat
    Patent number: 11266614
    Abstract: The present application concerns new formulations of belinostat suitable for oral administration, their process of preparation, the pharmaceutical compositions comprising said formulations and their uses thereof.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: March 8, 2022
    Assignee: ONXEO
    Inventors: Perrine Pivette, Caroline Lemarchand, Ian Yates, Corey Bloom
  • Diamine derivatives as inhibitors of leukotriene A4 hydrolase
    Patent number: 11267819
    Abstract: This invention is directed to compounds of formula (I): where r, q, R, R2, R3, R4, R5a, R5b, R5c, R6a, R6b, R6c, R7, R8, and R9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: March 8, 2022
    Assignee: Celltaxsis, LLC
    Inventors: Damian O. Arnaiz, Greg Brown, Emmanuel Claret, Arwed Cleve, David Davey, William Guilford, Seock-Kyu Khim, Thomas Kirkland, Monica J. Kochanny, Amy Liang, David Light, John Parkinson, Guo Ping Wei, Bin Ye